(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration (FDA) approved TUKYSA in combination with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable, locally advanced, or metastatic human epidermal growth factor 2-positive
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。